Abraxis BioScience

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Abraxis BioScience is a global biopharmaceutical company dedicated to meeting the needs of critically ill patients, with over 2000 employees worldwide.[1]


Abraxis' portfolio includes the world's first protein-based nanoparticle chemotherapeutic compound called nab Technology.[2] From this the company has developed Abraxane, a treatment for metastatic breast cancer.[3] On June 30, 2010, it was announced that Abraxis BioScience would be acquired by Celgene Corporation.[4]


  1. ^ BioPortfolio, 2007, "InDepth Summary", 10/11/2009
  2. ^ Abraxis BioScience, 2008, "Nab Technology", 10/11/2009
  3. ^ Hoovers, "[1]"
  4. ^ "Celgene To Acquire Abraxis BioScience Inc.", 6/30/10

External links[edit]